Navigation Links
Chemo + Radiation Best for Bladder Cancer, Study Finds
Date:4/18/2012

By Maureen Salamon
HealthDay Reporter

WEDNESDAY, April 18 (HealthDay News) -- The addition of two well-tolerated chemotherapy drugs to radiation therapy led to significantly longer survival rates among patients with muscle-invasive bladder cancer.

In a new study splitting 360 patients into groups receiving radiation alone or radiation plus chemotherapy, British researchers found that those undergoing combined therapies had a 67 percent rate of local disease-free survival after two years, compared with 54 percent in the radiation group. Five-year overall survival rates were 48 percent in the chemo-radiation group, compared with 35 percent in the radiation-only group.

"Overall, the results establish that the addition of chemotherapy to radiotherapy should become standard practice for organ-preserving treatments of bladder cancer," said Dr. Manish Vira, director of the fellowship program in urologic oncology at the Arthur Smith Institute for Urology in Lake Success, N.Y. "The tried-and-true treatment method is still [bladder removal] and certainly we are moving toward a more multi-disciplinary approach."

The study is published April 19 in the New England Journal of Medicine.

About 385,000 cases of bladder cancer are diagnosed annually worldwide, according to study authors, with the average age at diagnosis over 70. For those whose cancer has invaded the bladder muscle, five-year survival rates are about 45 percent regardless of treatment.

For younger, healthier patients, bladder removal -- known as radical cystectomy -- is considered the gold standard of care for invasive bladder cancer. But older patients with co-existing medical conditions may not be as well-equipped to tolerate complications of the procedure, experts said.

The new study, the largest late-stage trial of its kind, was conducted at 45 medical facilities in the United Kingdom. Patients were randomly assigned to undergo daily radiation alone or radiation along with two chemotherapy drugs, fluorouracil and mitomycin C. In addition to improved survival rates, the number of patients needing bladder removal as a "salvage therapy" -- because other treatments failed -- was lower among those receiving radiation plus chemotherapy.

Adverse effects from the chemotherapy -- including diarrhea, sore mouth or suppression of blood cell production -- were low among participants and were managed by lowering drug dosages, said study author Dr. Nicholas James, a professor of clinical oncology at the University of Birmingham. in England.

Cost of the chemotherapy drugs is relatively inexpensive, he said -- about $1,600, plus pharmacy and intravenous administration costs.

"We were pleasantly surprised by the overall results, particularly the low reported toxicity in the chemo-radiotherapy arm compared to the radiotherapy-only group," James said. "We feel the results are sufficient to change practice . . . the drugs are cheap and safety was good in an elderly population."

More information

The U.S. National Library of Medicine has more about bladder cancer.

SOURCES: Nicholas James, M.B., Ph.D., professor, clinical oncology, and co-director, Research and Development (Cancer) University Hospitals, University of Birmingham, England; Manish A. Vira, M.D., director, fellowship program in urologic oncology, the Arthur Smith Institute for Urology, Lake Success N.Y.; April 19, 2012, New England Journal of Medicine


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Adding drug to standard chemotherapy provides no survival benefit for older lung cancer patients
2. Chemotherapy proves life-saving for some leukemia patients who fail induction therapy
3. Experimental Chemo Combo for Colon Cancer Disappoints
4. Progress toward new chemotherapy agents
5. New genomic test spares patients chemotherapy with no adverse effect on survival
6. Drug makes leukemia more vulnerable to chemo
7. How chemotherapy becomes more effective
8. Chemo Brain May Linger 20 Years After Breast Cancer Treatment
9. First study on long-term cognitive effects of breast cancer chemotherapy finds subtle impairment among women who received CMF regimen
10. Aurora-A hinders tumor-suppressor to allow chemotherapy resistance
11. New combo of chemo and well-known malaria drug delivers double punch to tumors
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Chemo + Radiation Best for Bladder Cancer, Study Finds
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort to ... treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain management ... (SCD) is a disorder of the red blood cells, which can cause episodes of ...
(Date:6/24/2016)... ... June 24, 2016 , ... The ... in Dallas that it will receive two significant new grants to support its ... PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists for ...
(Date:6/24/2016)... San Francisco, CA (PRWEB) , ... June 24, ... ... at CitiDent, is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has ... , self-ligating Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , ...
(Date:6/24/2016)... ... ... of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair Minimum Wage’ ... 2020 and then adjusting it yearly to increase at the same rate as the median ... floor does not erode again, and make future increases more predictable. , The company is ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine ... Making in Emergency Medicine conference in Ponte Vedra Beach, FL. The awards honor ... Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , “With this ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... -- The Academy of Managed Care Pharmacy (AMCP) today ... allow biopharmaceutical companies to more easily share health care ... coverage decisions, a move that addresses the growing need ... The recommendations address restrictions in the sharing of product ... a prohibition that hinders decision makers from accessing HCEI ...
(Date:6/24/2016)... LEXINGTON, Mass. , June 24, 2016   ... specialty pharmaceutical company developing innovative inhaled drugs, announced today ... when Russell Investments reconstituted its comprehensive set ... 2016. "This is an important milestone for ... "It will increase shareholder awareness of our progress in ...
(Date:6/23/2016)... June 23, 2016 Any dentist who has made ... the current process. Many of them do not even offer ... difficulties and high laboratory costs involved. And those who ARE ... at such a high cost that the majority of today,s ... Dr. Parsa Zadeh , founder of Dental Evolutions Inc. ...
Breaking Medicine Technology: